Vetoquinol Past Earnings Performance
Past criteria checks 5/6
Vetoquinol has been growing earnings at an average annual rate of 15.3%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 8.8% per year. Vetoquinol's return on equity is 11%, and it has net margins of 10.5%.
Key information
15.3%
Earnings growth rate
16.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 8.8% |
| Return on equity | 11.0% |
| Net Margin | 10.5% |
| Next Earnings Update | 12 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vetoquinol makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 529 | 56 | 0 | 0 |
| 30 Sep 23 | 527 | 57 | 90 | 0 |
| 30 Jun 23 | 525 | 59 | 181 | 0 |
| 31 Mar 23 | 533 | 53 | 179 | 0 |
| 31 Dec 22 | 540 | 48 | 178 | 0 |
| 30 Sep 22 | 538 | 48 | 180 | 0 |
| 30 Jun 22 | 537 | 48 | 182 | 0 |
| 31 Mar 22 | 529 | 55 | 179 | 0 |
| 31 Dec 21 | 521 | 63 | 176 | 0 |
| 30 Sep 21 | 504 | 52 | 165 | 0 |
| 30 Jun 21 | 487 | 40 | 154 | 0 |
| 31 Mar 21 | 457 | 30 | 151 | 0 |
| 31 Dec 20 | 427 | 19 | 147 | 0 |
| 30 Sep 20 | 418 | 25 | 145 | 0 |
| 30 Jun 20 | 408 | 31 | 143 | 0 |
| 31 Mar 20 | 402 | 30 | 141 | 0 |
| 31 Dec 19 | 396 | 29 | 139 | 0 |
| 30 Sep 19 | 385 | 31 | 139 | 0 |
| 30 Jun 19 | 374 | 33 | 139 | 0 |
| 31 Mar 19 | 371 | 35 | 137 | 0 |
| 31 Dec 18 | 368 | 36 | 135 | 0 |
| 30 Sep 18 | 360 | 36 | 133 | 0 |
| 30 Jun 18 | 352 | 36 | 131 | 0 |
| 31 Mar 18 | 352 | 36 | 130 | 0 |
| 31 Dec 17 | 352 | 35 | 130 | 0 |
| 30 Sep 17 | 354 | 32 | 129 | 0 |
| 30 Jun 17 | 356 | 29 | 127 | 0 |
| 31 Mar 17 | 353 | 28 | 126 | 0 |
| 31 Dec 16 | 350 | 28 | 124 | 0 |
| 30 Sep 16 | 349 | 27 | 124 | 0 |
| 30 Jun 16 | 348 | 25 | 124 | 0 |
| 31 Mar 16 | 345 | 25 | 123 | 0 |
| 31 Dec 15 | 343 | 24 | 122 | 0 |
| 30 Sep 15 | 338 | 26 | 120 | 0 |
| 30 Jun 15 | 333 | 28 | 118 | 0 |
| 31 Mar 15 | 324 | 27 | 115 | 0 |
| 31 Dec 14 | 315 | 26 | 113 | 0 |
| 30 Sep 14 | 309 | 25 | 110 | 0 |
| 30 Jun 14 | 304 | 24 | 108 | 0 |
| 31 Mar 14 | 302 | 24 | 107 | 0 |
| 31 Dec 13 | 300 | 24 | 105 | 0 |
| 30 Sep 13 | 298 | 22 | 104 | 0 |
| 30 Jun 13 | 297 | 21 | 103 | 0 |
Quality Earnings: 0O1O has high quality earnings.
Growing Profit Margin: 0O1O's current net profit margins (10.5%) are higher than last year (8.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0O1O's earnings have grown by 15.3% per year over the past 5 years.
Accelerating Growth: 0O1O's earnings growth over the past year (15.8%) exceeds its 5-year average (15.3% per year).
Earnings vs Industry: 0O1O earnings growth over the past year (15.8%) exceeded the Pharmaceuticals industry 3.5%.
Return on Equity
High ROE: 0O1O's Return on Equity (11%) is considered low.